Table 2.

Risk factors for increasing pp65 antigenemia among 119 recipients of allogeneic HSCT

OR↑ Ag > 2× baselineOR↑ Ag > 5× baseline
95% CIP95% CIP
Univariate analysis       
 Donor CMV serostatus       
  Positive 1.0*   1.0*   
  Negative 2.5 1.2 -5.4 .02 2.9 1.3 -6.8 .01  
 Donor type       
  Matched sibling 1.0*   1.0*   
  Mismatched related 0.6 0.2 -2.6 .52 0.3 0.03 -2.3 .23 
  Unrelated 3.3 1.5 -7.5 .004 2.7 1.1 -6.4 .03 
 Conditioning       
  Non–TBI-containing 1.0*   1.0*   
  TBI-containing 3.4 1.4 -8.0 .006 4.1 1.5 -11.8 .008  
 Acute GVHD       
  Grades 0-1 1.0*   1.0*   
  Grades 2-4 3.9 1.3-11.1 .01 14.3 1.8 -110.7 .01 
  Grades 3-4 1.6 0.7 -3.6 .25 1.7 0.7 -4.1 .22 
 Steroid use at 1st Ag + ve       
  None 1.0*   1.0*   
  <1 mg/kg 4.1 0.9-17.4 .06 4.3 0.4 -51.3 .25  
  12 mg/kg 4.3 1.2-15.3 .03 14.3 1.7 -120.2 .01 
  ≥2 mg/kg 10.5 3.1-35.8 .0002 28.6 3.6 -229.7 .002  
Multivariate analysis       
 Conditioning       
  Non–TBI-containing 1.0*      
  TBI-containing 2.6 1.0 -6.8 .04    
 Steroid use at 1st Ag + ve       
  None 1.0*   1.0*   
  <1 mg/kg 5.0 1.0-24.5 .05 4.3 0.4 -51.3 .25  
  1-2 mg/kg 4.0 1.0-16.8 .06 14.3 1.7 -120.2 .01 
  ≥2 mg/kg 10.1 2.6-40.2 .001 28.6 3.6 -229.7 .002 
OR↑ Ag > 2× baselineOR↑ Ag > 5× baseline
95% CIP95% CIP
Univariate analysis       
 Donor CMV serostatus       
  Positive 1.0*   1.0*   
  Negative 2.5 1.2 -5.4 .02 2.9 1.3 -6.8 .01  
 Donor type       
  Matched sibling 1.0*   1.0*   
  Mismatched related 0.6 0.2 -2.6 .52 0.3 0.03 -2.3 .23 
  Unrelated 3.3 1.5 -7.5 .004 2.7 1.1 -6.4 .03 
 Conditioning       
  Non–TBI-containing 1.0*   1.0*   
  TBI-containing 3.4 1.4 -8.0 .006 4.1 1.5 -11.8 .008  
 Acute GVHD       
  Grades 0-1 1.0*   1.0*   
  Grades 2-4 3.9 1.3-11.1 .01 14.3 1.8 -110.7 .01 
  Grades 3-4 1.6 0.7 -3.6 .25 1.7 0.7 -4.1 .22 
 Steroid use at 1st Ag + ve       
  None 1.0*   1.0*   
  <1 mg/kg 4.1 0.9-17.4 .06 4.3 0.4 -51.3 .25  
  12 mg/kg 4.3 1.2-15.3 .03 14.3 1.7 -120.2 .01 
  ≥2 mg/kg 10.5 3.1-35.8 .0002 28.6 3.6 -229.7 .002  
Multivariate analysis       
 Conditioning       
  Non–TBI-containing 1.0*      
  TBI-containing 2.6 1.0 -6.8 .04    
 Steroid use at 1st Ag + ve       
  None 1.0*   1.0*   
  <1 mg/kg 5.0 1.0-24.5 .05 4.3 0.4 -51.3 .25  
  1-2 mg/kg 4.0 1.0-16.8 .06 14.3 1.7 -120.2 .01 
  ≥2 mg/kg 10.1 2.6-40.2 .001 28.6 3.6 -229.7 .002 

Variables found not significant in univariate analysis were age, gender, underlying disease, disease risk, and GVHD prophylaxis.

*

Reference category.

If GVHD occurred after a rise in antigenemia level, this was regarded as grades 0-1 in the regression model.

For > 2× baseline, the likelihood ratio test for adding donor type to the model above yielded P = .16; for donor CMV serostatus, P = .25; for grades 2-4 GVHD,P = .73. For > 5× baseline, the likelihood ratio test for adding TBI-containing conditioning to the model above yieldedP = .09; for donor type, P = .13; for donor CMV serostatus, P = .09; for grades 2-4 GVHD,P = .23.